ReviewFrontiers in endocrinology2026
Beyond celiac disease: the potential role of gluten in Hashimoto's thyroiditis.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Celiac disease (CD) and Hashimoto's thyroiditis (HT) frequently coexist, suggesting that shared mechanisms of autoimmunity extend beyond the intestine. In CD, the pathogenic role of gluten is firmly established; in HT, however, gluten is better viewed as a candidate modifier rather than a proven universal trigger. This review synthesizes current evidence on how gluten may influence the CD-HT axis through gut dysbiosis, epithelial barrier dysfunction, immune cross-reactivity, and epigenetic regulation. We also examine the clinical evidence for gluten-free diet (GFD) use in three settings: classical CD, CD-HT comorbidity, and HT without confirmed CD. Current data support lifelong GFD in CD and suggest that patients with both CD and HT may gain indirect thyroid-related benefit as intestinal inflammation improves. By contrast, evidence remains insufficient to recommend routine gluten withdrawal for all patients with non-celiac HT. Long-term GFD also carries practical and nutritional burdens that require professional supervision. Overall, the most defensible clinical approach is targeted screening for CD or other gluten-related disorders in selected HT patients, followed by individualized dietary counseling rather than universal restriction. Future work should prioritize mechanistically informed, adequately powered randomized trials to identify which thyroid-autoimmune phenotypes, if any, are most likely to benefit from gluten exclusion.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.